• xmlui.mirage2.page-structure.header.title
    • français
    • English
  • Help
  • Login
  • Language 
    • Français
    • English
View Item 
  •   BIRD Home
  • LEDa (UMR CNRS 8007, UMR IRD 260)
  • LEDa : Publications
  • View Item
  •   BIRD Home
  • LEDa (UMR CNRS 8007, UMR IRD 260)
  • LEDa : Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browse

BIRDResearch centres & CollectionsBy Issue DateAuthorsTitlesTypeThis CollectionBy Issue DateAuthorsTitlesType

My Account

LoginRegister

Statistics

Most Popular ItemsStatistics by CountryMost Popular Authors
Thumbnail - Request a copy

Use of real-world evidence in meta-analyses and cost-effectiveness models

Bowrin, Kevin; Briere, Jean-Baptiste; Lévy, Pierre; Toumi, Mondher; Millier, Aurélie (2020), Use of real-world evidence in meta-analyses and cost-effectiveness models, Journal of Medical Economics, 23, 10, p. 1053-1060. 10.1080/13696998.2020.1792917

Type
Article accepté pour publication ou publié
Date
2020-06
Journal name
Journal of Medical Economics
Volume
23
Number
10
Publisher
Taylor & Francis
Pages
1053-1060
Publication identifier
10.1080/13696998.2020.1792917
Metadata
Show full item record
Author(s)
Bowrin, Kevin
Bayer Corporation
Briere, Jean-Baptiste
BAYER AG
Lévy, Pierre
Laboratoire d'Economie et de Gestion des Organisations de Santé [Legos]
Laboratoire d'Economie de Dauphine [LEDa]
Toumi, Mondher
Centre d'études et de recherche sur les services de santé et la qualité de vie [CEReSS]
Millier, Aurélie
Creativ-Ceutical France
Abstract (EN)
Real-world evidence (RWE) provides external validity, supplementing and enhancing the randomized controlled trial data with valuable information on patient behaviors and outcomes, turning efficacy and safety results into real-world effectiveness and risks, but the use of RWE is associated with challenges. The objectives of this communication were to (1) summarize all guidance on how to conduct an RWE meta-analysis (MA) and how to develop an RWE cost-effectiveness model, (2) to describe our experience, challenges faced and solutions identified, (3) to provide recommendations on how to conduct such analyses. No formal guidelines on how to conduct an RWE MA or to develop an RWE cost-effectiveness model were identified. Using the context of non-vitamin K antagonist oral anticoagulants in stroke prevention in atrial fibrillation, we conducted an RWE MA, after having identified sources of uncertainty. We then implemented the results in an RWE cost-effectiveness model, defined as a model where all inputs come from RWE, including all parameters related to treatment effect. Based on challenges faced, our first recommendation relates to the necessity of conducting sensitivity analyses, either based on clinical or methodological considerations. Our second recommendation is the need for extensive collaboration with a wide range of experts, during the development of the analyses protocols, the implementation of the analyses and the interpretation of the results. RWE may address a number of gaps related to the treatment effect, and RWE economic evaluations for the treatment effect can provide extremely valuable insights into real-world economic value of interventions. As the increased recognition of the value of RWE could influence health technology assessment decision, and current practices, this communication supports the urgent need of more formal guidelines.
Subjects / Keywords
Anticoagulants; atrial fibrillation; meta-analysis; cost-effectiveness; real-world evidences; troke prevention
JEL
I20 - General
I19 - Other

Related items

Showing items related by title and author.

  • Thumbnail
    Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK 
    Bowrin, Kevin; Briere, Jean-Baptiste; Lévy, Pierre; Millier, Aurélie; Tardu, Jean; Toumi, Mondher (2020-06) Article accepté pour publication ou publié
  • Thumbnail
    Cost-effectiveness analyses using real-world data: an overview of the literature 
    Bowrin, Kevin; Briere, Jean-Baptiste; Lévy, Pierre; Millier, Aurélie; Clay, Emilie; Toumi, Mondher (2019) Article accepté pour publication ou publié
  • Thumbnail
    Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation 
    Briere, Jean-Baptiste; Wu, Olivia; Bowrin, Kevin; Millier, Aurélie; Toumi, Mondher; Taieb, Vanessa; Lévy, Pierre; Coleman, Craig I. (2019) Article accepté pour publication ou publié
  • Thumbnail
    Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation 
    Coleman, Craig I.; Briere, Jean-Baptiste; Fauchier, Laurent; Fauchier, Laurent; Lévy, Pierre; Bowrin, Kevin; Toumi, Mondher; Millier, Aurélie; Taieb, Vanessa; Wu, Olivia (2019) Article accepté pour publication ou publié
  • Thumbnail
    Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective 
    Lévy, Pierre; Smadja, David M.; Dorey, Julie; Toumi, Mondher; Meinecke, Anna-Katharina; Bowrin, Kevin; Briere, Jean-Baptiste (2019) Article accepté pour publication ou publié
Dauphine PSL Bibliothèque logo
Place du Maréchal de Lattre de Tassigny 75775 Paris Cedex 16
Phone: 01 44 05 40 94
Contact
Dauphine PSL logoEQUIS logoCreative Commons logo